T.TO — TELUS Corporation

TELUS operates one-third of Canada's wireless market through an oligopolistic structure that has produced industry-leading customer retention for over a decade, while simultaneously building TELUS Health into a global employee wellness platform covering 161 million lives — a business growing at 16% annually inside a stock that has declined 13.6% in the past year and now yields 9.6%. The problem underneath the attractive yield is that the $2.2 billion in annual free cash flow does not fully cover the approximately $2.6 billion distributed to shareholders annually, with the gap bridged by issuing new shares through a discounted dividend reinvestment plan that quietly dilutes unit holders who think they are collecting cash. Until free cash flow closes that gap, the headline yield overstates the real return, and the investment is interesting but requires a specific catalyst to be actionable.

---

The Canadian wireless industry entered 2026 at a peculiar juncture. For years, Rogers Communications, BCE's Bell, and TELUS enjoyed the most disciplined telecom oligopoly in the developed world — three carriers splitting a market of 40 million people, each investing billions annually in overlapping national networks, and each earning returns on that capital that would be the envy of their counterparts in the United States or Europe where four or five competitors dilute the economics considerably. The entry of Quebecor's Freedom Mobile as a genuine fourth national carrier, following the Shaw acquisition in 2023, disrupted that equilibrium. Freedom's aggressive pricing catalyzed an 18.2% national average decline in wireless tariffs during 2023, forcing the incumbents into promotional pricing cycles that compressed the revenue per subscriber metric that has driven the sector's valuation for a generation. The industry-wide response — improved network quality, bundled home internet and wireless offers, loyalty programs — has been rational, but the competitive damage to average revenue per user has proved persistent. As of early 2026, Canadian wireless carriers are managing a market where subscriber counts are growing modestly while the revenue each subscriber generates is declining at a rate that outstrips the volume gains.

The Canadian telecommunications market is large and structurally concentrated. Total telecom and pay-TV service revenue across all providers was approximately $38.2 billion in 2024, expected to grow at a 2.3% compound annual rate to $42.8 billion by 2029 — growth that reflects demographic expansion, data consumption increases, and gradual fibre penetration rather than any fundamental acceleration. Rogers, Bell, and TELUS, collectively with their flanker brands, control roughly 90% of wireless revenue. The spectrum costs, network infrastructure investment, and regulatory complexity required to compete at national scale constitute a genuine barrier to entry: Freedom Mobile's entry required Quebecor's acquisition of an existing carrier with existing spectrum, network, and customers. A de novo national wireless carrier in Canada is effectively impossible. What this structural concentration means is that while the three incumbents compete vigorously on price and promotion, no one is going to fundamentally undercut the economics of the oligopoly. The network is the asset; the network requires continuous multi-billion-dollar capital investment; that capital investment justifies pricing that preserves adequate returns. The danger is not structural disruption but margin compression within the existing structure — and that compression is ongoing.

TELUS is the third-largest carrier by revenue but arguably the best-positioned operationally for the transition ahead. The company serves approximately 10.2 million mobile phone subscribers and 20.5 million total telecom subscribers across wireless, wireline, internet, and connected devices. Its PureFibre network has been built aggressively — TELUS has committed approximately $70 billion to Canadian infrastructure through 2029 — and the company's western Canadian geography, where it has the highest network share and densest fibre penetration, provides a geographic stronghold that Rogers and Bell cannot easily contest. Beyond the core telecom, TELUS has built two distinct business platforms that are increasingly material to the investment thesis: TELUS Health, which provides employee health benefits management, virtual care, and pharmacy solutions to employers across North America, Australia, and the United Kingdom; and TELUS Digital (formerly TELUS International), which provides AI-enabled digital customer experience services to technology companies and other large enterprises globally. The three-segment structure — telco infrastructure, health platform, digital services — makes TELUS more complex to analyze than a pure wireless carrier, and that complexity may be part of what explains the current valuation discount to where the business should trade if its parts were appropriately credited.

The moat argument has two layers, and they need to be assessed separately. The core wireless business has a structural advantage rooted in the oligopoly economics described above — building a competing national wireless network is prohibitively expensive, spectrum is finite and regulatory allocated, and the incumbents' existing customer relationships have real switching friction. TELUS has maintained a monthly postpaid mobile churn rate below 1% for twelve consecutive years, a record that demonstrates genuine customer retention even as pricing competition intensified. The health business layer has a different and in some ways more interesting moat: TELUS Health's platform manages employee health benefits, virtual care access, and pharmacy benefits for corporate clients across 161 million covered lives globally. The switching cost in health benefits management is institutional — changing the provider for employee health programs requires re-contracting across HR systems, insurer relationships, and employee communication, at a cost in management time and program disruption that most employers prefer to avoid. A platform that already administers benefits for a company's 10,000 employees has a meaningful incumbent advantage at renewal.

The honest moat comparison for the wireless business, however, shows narrowing differentiation:

Carrier	Postpaid Mobile Churn (monthly)	Mobile Phone ARPU (Q2 2025)	2025 Network Awards (Opensignal)	5G Population Coverage
TELUS	1.06%	$56.58 CAD	Reliability & consistency (shared)	>85%
Bell	~1.0%	Not disclosed separately	Best 5G Network, Fastest Mobile Network, Fastest 5G, Best Gaming	>85%
Rogers	~1.1–1.2%	Not disclosed separately	Best Mobile Video, Best 5G Video	>85%

TELUS won no network performance awards in the most recent semi-annual Opensignal testing covering the second half of 2025. Bell took top honours across five categories. The competitive differentiation that once supported TELUS's premium brand position in wireless has not disappeared — the reliability and consistency metrics where TELUS ties with Rogers reflect genuinely high network quality — but it is no longer a clear differentiator. When three networks covering 85% of the population with 5G technology produce essentially the same experience for the typical user, pricing becomes the decisive variable, and pricing is the variable that has been declining. The wireless moat remains — the physical infrastructure barrier is real — but the within-oligopoly quality premium that would support ARPU recovery is not obviously in TELUS's favor based on current network benchmark data.

The financial profile of TELUS requires careful separation of reported metrics from the underlying economic reality. Total consolidated revenue for the trailing twelve months through FY2025 was approximately CAD $20.45 billion; core service revenue was CAD $14.56 billion, a slight decline from 2024, primarily from lower equipment sales which are low-margin pass-through items rather than economically meaningful revenue. The more important metrics: adjusted EBITDA grew 4% in 2025 with 230 basis points of margin expansion, and free cash flow reached a record CAD $2.2 billion, 11% above the prior year. GAAP net income was approximately CAD $1.18 billion against $20.45 billion in revenue — a thin GAAP margin that reflects substantial depreciation and amortization charges on a capital-intensive infrastructure business as well as interest expense on $28.2 billion in net debt. The GAAP P/E ratio of approximately 23 times is not the right valuation metric for a telco; the relevant denominators are EBITDA and free cash flow. On EV/EBITDA of 11.1 times and FCF yield of 7.9%, TELUS is not expensively priced.

The critical accounting issue that every investor in TELUS must confront directly is the relationship between free cash flow and the dividend. TELUS pays CAD $1.67 per share annually. At approximately 1.56 billion shares outstanding, the total annual dividend obligation is approximately $2.61 billion. FY2025 free cash flow was $2.2 billion. The gap — approximately $410 million — is funded primarily through the discounted dividend reinvestment plan: shareholders who participate in the DRIP receive new shares issued at a 3-5% discount to market price rather than cash. The result is that TELUS's headline 9.6% dividend yield is not a yield in the conventional sense — it is a combination of approximately 7.9% FCF yield and approximately 1.7% that is financed by issuing equity at a discount. This matters because shareholders who receive new shares through the DRIP rather than cash are not being paid — they are having their ownership diluted alongside everyone else's. Management began scaling back the DRIP discount in early 2026, which is the right direction but means more cash must now go out the door, which requires the 2026 FCF guidance of $2.45 billion to actually arrive on schedule.

Darren Entwistle has been President and CEO of TELUS since 2000 — twenty-six years during which the company transformed from a regional BC telephone company into a diversified national telecommunications and health services platform. That record is genuinely impressive: TELUS built PureFibre, assembled TELUS Health through a series of acquisitions including the $3.7 billion LifeWorks deal in 2022, and maintained customer retention metrics that consistently outperformed peers. Entwistle will retire June 30, 2026; Victor Dodig, who served as CEO of CIBC for a decade and brings deep capital markets and restructuring expertise, assumes the presidency July 1. The transition is significant — management continuity is one of TELUS's historical strengths, and twenty-six years of institutional knowledge does not transfer on a handover date. Insider conviction is visible in the numbers: in November and December 2025, Entwistle and several board members collectively purchased 357,090 TELUS shares, Entwistle has taken his entire salary in TELUS shares since 2024, and the company launched a $500 million normal course issuer bid in December 2025 — buybacks that partially counteract the DRIP dilution. The insider buying is a meaningful signal of alignment. The DRIP structure is a countervailing signal that alignment has limits.

The five metrics that matter for the TELUS investment thesis over the next three years are: mobile ARPU (the price the network is earning per subscriber), free cash flow (the cash available after maintaining and growing the network), TELUS Health adjusted EBITDA growth (the growth engine beyond core telco), net debt to EBITDA (the de-leveraging track), and mobile phone subscribers (the volume base that determines total wireless revenue). Together they show whether the volume growth is winning against the ARPU headwind, whether the health business is scaling as promised, and whether the balance sheet is being repaired at the rate management has committed to.

Period	Mobile ARPU (CAD)	Mobile Subs (M)	Free Cash Flow ($B)	TELUS Health Rev Growth	Net Debt / EBITDA
FY2023	~$61	~9.9	~$1.9	High (LifeWorks yr 1)	~3.9x
Q1 2024	$59.31	~10.0	—	—	~3.9x
Q2 2024	$58.49	~10.1	—	—	~3.8x
FY2024	~$58.50	~10.1	~$2.0	~12%	~3.7x
Q1 2025	$57.13	~10.2	—	+12%	~3.6x
Q2 2025	$56.58	~10.25	—	—	~3.5x
Q3 2025	$57.21	~10.3	—	—	~3.4x
FY2025	~$57	~10.3	$2.2B (record)	+16%	3.4x
2026 Target	—	—	~$2.45B	—	≤3.3x

The table contains two stories running simultaneously. The negative story is in the ARPU column: mobile average revenue per user has declined from approximately $61 in 2023 to approximately $57 in 2025, a drop of roughly 6-7% over two years driven by Quebecor/Freedom's pricing pressure and the competitive response it forced from the incumbents. The subscriber column partially offsets this — mobile phone subscribers grew from 9.9 million to 10.3 million, a 4% increase that is real but insufficient to compensate for a 6-7% ARPU decline in total wireless revenue. The net result is that core wireless is generating less revenue per dollar of network asset than it was two years ago, and the trajectory of ARPU will define whether this is a temporary dislocation or a structural ratchet lower. Q3 2025 showed a slight sequential ARPU recovery to $57.21 from $56.58 in Q2 — the first quarterly improvement in the series — but the year-over-year decline remained negative at approximately 2.8%. Whether Q3 2025 represents the inflection point that ARPU stabilization arguments require is the critical question the next several quarters will answer.

The positive story is the FCF trajectory and TELUS Health. FCF grew from approximately $1.9 billion in 2023 to a record $2.2 billion in 2025, driven by capex reductions (from over $3 billion annually during peak PureFibre construction to $2.3 billion in 2026), EBITDA growth, and reduced working capital requirements. TELUS Health grew revenue 16% in 2025 with adjusted EBITDA up 29%, reflecting the LifeWorks integration producing $431 million in annualized synergies while the platform expanded coverage to 161 million lives across North America, Australia, and the United Kingdom. TELUS Health is now the clearest argument for why TELUS trades at a discount to fair value: a healthcare technology platform covering 161 million lives globally and growing EBITDA at 29% is not worth the implied sum-of-parts value the current consolidated stock price suggests. Management acknowledged this directly by disclosing it is actively pursuing a strategic partner for TELUS Health — a process that, if successful, could surface the health platform's value as a separate capital event and simultaneously generate proceeds to accelerate deleveraging.

The penetration story for TELUS Health is genuinely compelling in isolation. The global employee health benefits and wellness management market spans hundreds of millions of employed people in developed economies — conservatively, 500 million to 700 million individuals in North America, Europe, and Australia who are covered by employer health plans. At 161 million covered lives, TELUS Health has captured approximately 23-32% of that addressable population in its operating geographies. That leaves 70-77% of the market either unserved by integrated health platforms or served by fragmented point solutions that TELUS Health's end-to-end employee wellness approach could displace. TELUS Health grew from $0 to 161 million covered lives primarily through acquisition (LifeWorks in 2022, Workplace Options in 2024), and the platform economics — recurring benefit administration contracts, high switching costs, inflation-linked pricing — match the profile of a business where scale creates durable advantage. If TELUS Health were a standalone public company growing at 16% revenue and 29% EBITDA, the market would assign it a multiple appropriate for a health technology platform, not the blended utility multiple that constrains the consolidated TELUS stock.

At CAD $17.88 per share with approximately 1.56 billion shares outstanding, TELUS carries a market capitalization of approximately CAD $27.91 billion and net debt of approximately $28.20 billion, for a total enterprise value of approximately $56.1 billion. Against management's guidance for 2026 adjusted EBITDA growth of 2-4%, the enterprise value implies EV/EBITDA of approximately 11 times — reasonable for a diversified telco with a growing health platform but not obviously cheap. The FCF yield of approximately 7.9% on market cap is the more compelling entry-point metric: at 7.9% FCF yield, a patient investor in a business with stable-to-growing earnings collects a real return while waiting for re-rating catalysts to arrive. The problem, again, is the dividend gap: $2.2 billion FCF against $2.6 billion in total dividend obligations means the apparent 9.6% yield is not actually 9.6% in cash terms for investors who hold through the DRIP cycle.

The conclusion from this analysis is precisely calibrated by two specific unresolved questions. First: will mobile ARPU stabilize? The Q3 2025 sequential improvement to $57.21 is the first piece of evidence in the right direction. If Q4 2025, Q1 2026, and Q2 2026 each show year-over-year ARPU declines moderating and eventually going flat, the core wireless revenue outlook changes from "deteriorating" to "stable," which is a meaningful re-rating event for a business priced as though deterioration continues indefinitely. Second: will FCF close the dividend coverage gap? The 2026 guidance of $2.45 billion FCF against an approximately $2.6 billion dividend obligation still leaves a gap, but the gap is narrowing. If FCF reaches approximately $2.7 billion — consistent with management's three-year trajectory — the DRIP dilution becomes unnecessary, the dividend is genuinely 9.6% in cash, and the income investment thesis becomes straightforwardly compelling. Neither of these events has arrived yet.

The most intelligent bear argument is that TELUS's leverage tells the real story: $28.2 billion in net debt against a $27.9 billion equity market cap means the bondholders effectively own as much of the enterprise as the shareholders, and in any scenario where EBITDA growth slows or interest rates remain elevated at refinancing, the equity cushion is thin. The counter is that TELUS's cash flows are contracted through long-term wireless subscriber relationships and health platform contracts — they are not cyclically volatile in the way that a retailer's or manufacturer's cash flows are — and that regulated infrastructure businesses globally carry leverage ratios of 3-5 times EBITDA routinely, without their equity being at structural risk. The counter works as long as EBITDA is stable or growing, which the 2025 results and 2026 guidance support. But at 3.4 times net debt to EBITDA in a world of structurally higher interest rates than the decade following 2010, the leverage is not comfortable — it is manageable.

What would change the conclusion: ARPU stabilization, demonstrated through two or three consecutive quarters of year-over-year declines moderating toward zero, would remove the core uncertainty about wireless revenue trajectory and make the FCF outlook more credible. Alternatively, a TELUS Health strategic partnership or partial monetization at a multiple consistent with health technology platform valuations — in the 18-25 times EBITDA range that comparable digital health companies command — would crystallize value from the health platform and simultaneously reduce consolidated leverage to approximately 3.0 times or better, enabling the DRIP to be wound down entirely and the headline yield to become a genuine cash yield. Either catalyst transforms the investment from "interesting" to "compelling." Both together would be extraordinary.

The 9.6% yield is real enough to pay for the waiting. The question is whether what arrives at the end of the wait is worth the dilution incurred along the way.